Soleus Capital
Venture capitalGreenwich · Late Stage · 2 people tracked
Also known as SOLEUS CAPITAL MANAGEMENT, L.P.
Find your way into Soleus Capital
565 people in our graph share verified history with the Soleus Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Soleus Capital invests across the healthcare and life sciences sector, targeting innovative areas such as biotech, medtech, diagnostics, and genomics. The firm invests across the full healthcare lifecycle, backing companies ranging from developmental-stage ventures through to commercial-stage businesses.
Source: firm website, verified Sep 15, 2026.
Team · 2 people
from public directoriesWhat they invest in
from 16 of 16 portfolio companiesHealthtech ×12Biotech ×11Medical Devices ×6Digital Health ×4AI & Machine Learning ×3Deep Tech ×3Data & Infrastructure ×1Hardware ×1
HQs:United States×13
Investments · showing 15 of 16
founders shown can be your intro pathBy year:2026 · 22025 · 32024 · 12021 · 52020 · 112 dated
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSteven Russell(Chief Medical Officer)inMark Hopman(Chief Commercial Officer)in
Co-investorsOmega FundsRTW Investments L.P.
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+7 more
.png)
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersOrbiMedPeregrine VenturesPitango+2 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos CapitalRA CapitalBiotechnology Value Fund
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+5 more
Field Trip Health provides ketamine-assisted therapy for treatment-resistant depression and anxiety, offering rapid symptom relief through clinically monitored ketamine administration combined with psychotherapy.
Digital HealthHealthtechMedical DevicesMental Health
Co-investorsFrontera Technology VenturesEarl Grey CapitalJennison AssociatesPura Vida InvestmentsSphera Funds Management
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.
Data & InfrastructureMarketing TechMedia & Entertainment
Co-investorsHaatchHorizon Technology FinanceJanus Henderson InvestorsSahsen VenturesSARAS CAPITAL
Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.
BiotechDigital HealthHealthtechMedical DevicesNatick, US
Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)
Co-investorsCatalio Capital Management, LPHB Ventures
SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.
BiotechDeep TechHealthtechBoulder, US
Larry Gold(Director)inLarry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)in
BoardCharles Lillis(Director)Youichi Yabuuchi(Director)
Co-investorsForesite CapitalKhosla VenturesCasdin CapitalMagnetar CapitalReimagined VenturesT. Rowe Price
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.venBio Global StrategicVivo Capital
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupClarusPolaris Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 2
2 IPOsBeta Bionics, IncNASDAQ: BBNXParabilis MedicinesNASDAQ: PBLS
Portfolio news
latest coverage across their companies
Abcuro · clinicaltrialsarena.com · Aug 19, 2026
Arcellx · biobuzz.io · Aug 14, 2026
Beta Bionics, Inc · tradingview.com · Aug 11, 2026
SomaLogic · aol.com · Aug 4, 2026
Parabilis Medicines · pharmexec.com · Jun 19, 2026
Longeviti Neuro Solutions · technical.ly · Sep 11, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Beta Bionics, Inc | 5.4% | $17.00 | Jan 2025 | $39M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Soleus Capital made?
- Soleus Capital has 16 tracked investments, 2 of which have exited, including 5 dated in the last 24 months.
- What stage does Soleus Capital invest at?
- Soleus Capital invests at the Late Stage stage.
- What sectors does Soleus Capital focus on?
- Soleus Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Soleus Capital located?
- Soleus Capital is headquartered in Greenwich, US.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.